Elicio Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Elicio Therapeutics Inc ELTX.OQ reported a quarterly adjusted loss of 66 cents​​ per share for the quarter ended June 30, lower than the same quarter last year, when the company reported EPS of -64 cents. The mean expectation of two analysts for the quarter was for a loss of 68 cents per share. Wall Street expected results to range from -69 cents to -68 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Elicio Therapeutics Inc's reported EPS for the quarter was a loss of 66 cents​.

• The company reported a quarterly loss of $10.56 million.

• Elicio Therapeutics Inc shares had risen by 19.2% this quarter and gained 80.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 3.3% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Elicio Therapeutics Inc is $12.50, about 26.4% above its last closing price of $9.20

This summary was machine generated from LSEG data August 11 at 09:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)